(Bloomberg) -- Teva Pharmaceutical Industries Ltd. raised the bottom end of its earnings and sales forecasts as Chief Executive Officer Kare Schultz’s cost-cutting plan remained on target.
ADVERTISEMENT
- Adjusted earnings for the year will be $2.30 a share to $2.50, the Israeli drugmaker said. It had previously seen a minimum of $2.20 a share.
- Teva has nearly reached its $3 billion cost-reduction goal for the year.
ADVERTISEMENT
Key Insights
- For most investors, Teva’s earnings are a sideshow to their main concern -- the scope of the company’s liability in the U.S. opioid addiction epidemic. Analysts are likely to pepper management with requests for detail on their upcoming call.
- Sales of migraine treatment Ajovy missed analysts’ estimates. Schultz has said that the drug will one day help replace the revenue from aging MS drug Copaxone, whose blockbuster sales have been eroded by cheaper competition. Its quarterly sales beat estimates.
- Total debt fell to $26.9 billion. Schultz’s signature initiative has been slashing expenses and paying back debt.
- Teva appointed Eli Kalif, 47, as chief financial officer. He was previously senior vice president of finance at Flex Ltd., a California-based technology design and manufacturing firm.
Market Reaction
- Teva shares rose as much as 5.8% in early trading before U.S. markets opened. The American depositary receipts have lost 47% this year.
Get More
- See more details.
- Read the statement.
©2019 Bloomberg L.P.